HUE046567T2 - Hepatitis B mag protein allosztérikus modulátorok - Google Patents
Hepatitis B mag protein allosztérikus modulátorokInfo
- Publication number
- HUE046567T2 HUE046567T2 HUE15761201A HUE15761201A HUE046567T2 HU E046567 T2 HUE046567 T2 HU E046567T2 HU E15761201 A HUE15761201 A HU E15761201A HU E15761201 A HUE15761201 A HU E15761201A HU E046567 T2 HUE046567 T2 HU E046567T2
- Authority
- HU
- Hungary
- Prior art keywords
- hepatitis
- core protein
- allosteric modulators
- protein allosteric
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/14—[b, e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/16—[b, f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461952467P | 2014-03-13 | 2014-03-13 | |
US201462010025P | 2014-06-10 | 2014-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE046567T2 true HUE046567T2 (hu) | 2020-03-30 |
Family
ID=54072461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE15761201A HUE046567T2 (hu) | 2014-03-13 | 2015-03-13 | Hepatitis B mag protein allosztérikus modulátorok |
Country Status (23)
Country | Link |
---|---|
US (3) | US10183936B2 (hu) |
EP (3) | EP3116316B1 (hu) |
JP (2) | JP6602311B2 (hu) |
KR (1) | KR102363174B1 (hu) |
CN (2) | CN110437153A (hu) |
AP (1) | AP2016009477A0 (hu) |
AU (2) | AU2015229174B2 (hu) |
CA (1) | CA2942533C (hu) |
CL (1) | CL2016002269A1 (hu) |
DK (1) | DK3116316T3 (hu) |
DO (1) | DOP2016000233A (hu) |
ES (1) | ES2748029T3 (hu) |
HR (1) | HRP20191444T1 (hu) |
HU (1) | HUE046567T2 (hu) |
IL (3) | IL247575B (hu) |
MX (2) | MX363600B (hu) |
PH (1) | PH12016501762A1 (hu) |
PL (1) | PL3116316T3 (hu) |
PT (1) | PT3116316T (hu) |
RS (1) | RS59430B1 (hu) |
SG (2) | SG10202001506UA (hu) |
WO (1) | WO2015138895A1 (hu) |
ZA (1) | ZA201606209B (hu) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2649410T3 (es) | 2011-12-21 | 2018-01-11 | Novira Therapeutics Inc. | Agentes antivirales para la hepatitis B |
TW201920090A (zh) | 2012-08-28 | 2019-06-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基-芳醯胺類及其做為治療b型肝炎之醫藥劑的用途 |
CA2899706C (en) | 2013-02-28 | 2021-10-19 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
WO2014161888A1 (en) | 2013-04-03 | 2014-10-09 | Janssen R&D Ireland | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
RS57999B1 (sr) | 2013-05-17 | 2019-01-31 | Janssen Sciences Ireland Uc | Derivati sulfamoiltiofenamida i njihova primena kao lekovi za tretman hepatitisa b |
AU2014294997B2 (en) | 2013-07-25 | 2018-03-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
KR102290189B1 (ko) | 2013-10-23 | 2021-08-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 카르복스아미드 유도체 및 b형 간염 치료용 의약으로서의 이의 용도 |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
MX2016009449A (es) | 2014-02-05 | 2016-10-13 | Novira Therapeutics Inc | Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb). |
KR20160110419A (ko) | 2014-02-06 | 2016-09-21 | 얀센 사이언시즈 아일랜드 유씨 | 술파모일피롤아미드 유도체 및 b형 간염 치료용 의약으로서의 이의 용도 |
HUE046567T2 (hu) | 2014-03-13 | 2020-03-30 | Univ Indiana Res & Tech Corp | Hepatitis B mag protein allosztérikus modulátorok |
EP3271019A1 (en) | 2015-03-19 | 2018-01-24 | Novira Therapeutics Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
CN108025034B (zh) * | 2015-07-15 | 2022-09-30 | 新加坡科技研究局 | 乙型肝炎病毒复制的调控 |
TWI721016B (zh) | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
JP6845231B2 (ja) | 2015-09-29 | 2021-03-17 | ノヴィラ・セラピューティクス・インコーポレイテッド | B型肝炎抗ウイルス薬の結晶形態 |
CA3021068A1 (en) | 2016-04-15 | 2017-10-19 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
EP3454862A4 (en) | 2016-05-10 | 2020-02-12 | C4 Therapeutics, Inc. | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
CN109937201A (zh) * | 2016-09-15 | 2019-06-25 | 组装生物科学股份有限公司 | 乙型肝炎核心蛋白调节剂 |
CN110036008A (zh) * | 2016-10-03 | 2019-07-19 | 西吉隆医疗股份有限公司 | 化合物、装置及其用途 |
KR102522060B1 (ko) | 2016-11-07 | 2023-04-14 | 아뷰터스 바이오파마 코포레이션 | 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법 |
CN106632177A (zh) * | 2016-12-05 | 2017-05-10 | 万特制药(海南)有限公司 | 雷美替胺中间体的制备方法 |
WO2018153285A1 (zh) * | 2017-02-23 | 2018-08-30 | 福建广生堂药业股份有限公司 | 三并环类化合物及其应用 |
BR112019018230A2 (pt) | 2017-03-02 | 2020-07-21 | Assembly Biosciences, Inc. | compostos de sulfamida cíclica e métodos de sua utilização |
WO2018169907A1 (en) * | 2017-03-13 | 2018-09-20 | Assembly Biosciences, Inc. | Process for making hepatitis b core protein modulators |
MA49014A (fr) | 2017-03-21 | 2020-02-05 | Arbutus Biopharma Corp | Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant |
ES2946917T3 (es) | 2017-07-21 | 2023-07-27 | Antabio Sas | Compuestos químicos |
EP3704127A1 (en) | 2017-11-02 | 2020-09-09 | AiCuris GmbH & Co. KG | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
CU20200045A7 (es) | 2017-11-02 | 2021-03-11 | Aicuris Gmbh & Co Kg | Derivados de indol-2-carboxamidas sustituidos con pirazolo-piperidina activos contra el virus de la hepatitis b (vhb) |
BR112020018601A2 (pt) | 2018-03-14 | 2020-12-29 | Janssen Sciences Ireland Unlimited Company | Regime de dosagem de modulador de montagem de capsídeo |
CN112334137A (zh) * | 2018-05-03 | 2021-02-05 | 埃默里大学 | 用于nash和其他代谢紊乱的孤儿核受体调节剂 |
CN110627752B (zh) * | 2018-06-25 | 2021-08-17 | 新发药业有限公司 | 一种3-氨甲基四氢呋喃的制备方法 |
CN108863884B (zh) * | 2018-07-26 | 2020-07-03 | 南京富润凯德生物医药有限公司 | 一种用dast试剂作为消除试剂合成共轭硝基烯取代系列衍生物的方法 |
US11952388B2 (en) | 2018-08-23 | 2024-04-09 | Fujian Akeylink Biotechnology Co., Ltd. | Crystal form of tri-cycle compound and application thereof |
UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
UY38439A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
AR117188A1 (es) | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
UY38435A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) |
AR116947A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
TW202045499A (zh) | 2019-02-22 | 2020-12-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用於治療hbv感染或hbv誘發疾病之醯胺衍生物 |
US20220227785A1 (en) | 2019-04-30 | 2022-07-21 | Aicuris Gmbh & Co. Kg | Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv) |
CU20210088A7 (es) | 2019-04-30 | 2022-06-06 | Aicuris Gmbh & Co Kg | Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
CN113748113A (zh) | 2019-04-30 | 2021-12-03 | 艾库里斯有限及两合公司 | 具有抗乙型肝炎病毒(hbv)活性的新型吲哚嗪-2-甲酰胺类化合物 |
JP2022533008A (ja) | 2019-04-30 | 2022-07-21 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | B型肝炎ウイルス(hbv)に対し活性な新規のオキサリルピペラジン |
CN113795486A (zh) | 2019-05-06 | 2021-12-14 | 爱尔兰詹森科学公司 | 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物 |
MA56031A (fr) * | 2019-05-24 | 2022-04-06 | Assembly Biosciences Inc | Compositions pharmaceutiques pour le traitement du vhb |
CN110526878A (zh) * | 2019-09-16 | 2019-12-03 | 成都睿智化学研究有限公司 | 一种2-(噁唑基)乙胺的制备方法 |
CN111072551A (zh) * | 2019-12-30 | 2020-04-28 | 上海睿瓦科技有限公司 | 催化氢化一步法制取哌啶胺的方法 |
CN115843294A (zh) * | 2020-04-22 | 2023-03-24 | 组装生物科学股份有限公司 | 用于治疗hbv的5元杂芳基甲酰胺化合物 |
CN113135848A (zh) * | 2021-04-26 | 2021-07-20 | 深圳市华先医药科技有限公司 | 一种巯基烯酯类化合物的制备方法 |
CN113636960A (zh) * | 2021-08-24 | 2021-11-12 | 上海皓元医药股份有限公司 | 一种2-(氯磺酰基)环己烷-1-烯甲酸乙酯衍生物的制备方法 |
CN113717080A (zh) * | 2021-10-09 | 2021-11-30 | 西安瑞联新材料股份有限公司 | 一种4-氯-2-氰基苯磺酰氯的合成方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1480553A (en) | 1976-06-03 | 1977-07-20 | Pfizer Ltd | Tricyclic sulphonamides |
JPS58225074A (ja) * | 1982-06-25 | 1983-12-27 | Chugai Pharmaceut Co Ltd | ジベンゾオキサゼピン誘導体 |
GB9109557D0 (en) * | 1991-05-02 | 1991-06-26 | Wellcome Found | Chemical compounds |
US5512563A (en) * | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
JP2007527412A (ja) * | 2003-10-24 | 2007-09-27 | エグゼリクシス, インコーポレイテッド | Taoキナーゼモジュレーターおよび使用方法 |
DE102004004928A1 (de) * | 2004-01-31 | 2005-08-18 | Bayer Healthcare Ag | Dibenzoxazepine II |
CA2625423A1 (en) * | 2005-10-17 | 2007-04-26 | Acadia Pharmaceuticals Inc. | Cb-1 modulating compounds and their use |
US20070105835A1 (en) | 2005-11-07 | 2007-05-10 | Kazantsev Aleksey G | Compositions and methods for modulating poly(ADP-ribose) polymerase activity |
WO2008036139A2 (en) | 2006-06-07 | 2008-03-27 | The Regents Of The University Of California | Inhibitors of mshc and homologs thereof, and methods of identifying same |
WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
CA2731224A1 (en) | 2008-07-23 | 2010-01-28 | Sanjay A. Desai | Inhibitors of the plasmodial surface anion channel as antimalarials |
WO2011075607A1 (en) * | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
WO2012045194A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
EP2726459B1 (en) | 2011-07-01 | 2019-09-11 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
US9968650B2 (en) | 2011-07-13 | 2018-05-15 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
JP6162144B2 (ja) | 2012-01-06 | 2017-07-19 | ヤンセン・サイエンシズ・アイルランド・ユーシー | 4,4−二置換−1,4−ジヒドロピリミジン、及びb型肝炎の処置のための医薬としてのその使用 |
TW201920090A (zh) | 2012-08-28 | 2019-06-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基-芳醯胺類及其做為治療b型肝炎之醫藥劑的用途 |
BR112015004161B8 (pt) | 2012-08-28 | 2022-11-08 | Janssen Sciences Ireland Uc | Derivado bicíclico fusionado de sulfamoíla e seu uso no tratamento e prevenção de infecção por vírus da hepatite b, bem como composição farmacêutica e produto que o compreende |
EP2892893B2 (en) | 2012-09-10 | 2019-10-16 | F.Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
CA2889892A1 (en) | 2012-11-09 | 2014-05-15 | Indiana University Research And Technology Corporation | Alternative uses for hbv assembly effectors |
SG11201503997VA (en) | 2012-12-06 | 2015-06-29 | Baruch S Blumberg Inst | Functionalized benzamide derivatives as antiviral agents against hbv infection |
SG10201803698UA (en) | 2012-12-27 | 2018-06-28 | Univ Drexel | Novel antiviral agents against hbv infection |
RU2519546C1 (ru) | 2013-01-16 | 2014-06-10 | Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а |
CA2899706C (en) | 2013-02-28 | 2021-10-19 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
UA120248C2 (uk) | 2013-03-15 | 2019-11-11 | Селджен Кар Ллс | Гетероарильні сполуки та їх застосування |
WO2014161888A1 (en) | 2013-04-03 | 2014-10-09 | Janssen R&D Ireland | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
EA201592126A1 (ru) | 2013-05-17 | 2016-05-31 | Ф. Хоффманн-Ля Рош Аг | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b |
RS57999B1 (sr) | 2013-05-17 | 2019-01-31 | Janssen Sciences Ireland Uc | Derivati sulfamoiltiofenamida i njihova primena kao lekovi za tretman hepatitisa b |
KR20160021277A (ko) | 2013-06-19 | 2016-02-24 | 세라곤 파마슈티컬스, 인크. | 에스트로겐 수용체 조절제 및 이의 용도 |
EP3027612B1 (en) * | 2013-07-29 | 2018-10-10 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists |
HUE046567T2 (hu) | 2014-03-13 | 2020-03-30 | Univ Indiana Res & Tech Corp | Hepatitis B mag protein allosztérikus modulátorok |
PL3154949T3 (pl) | 2014-06-10 | 2018-08-31 | Basf Se | PODSTAWIONE ZWIĄZKI [1,2,4]TRIAZOLOWE i IMIDAZOLOWE JAKO FUNGICYDY |
TWI721016B (zh) | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
US10811219B2 (en) | 2018-08-07 | 2020-10-20 | Applied Materials Israel Ltd. | Method for evaluating a region of an object |
-
2015
- 2015-03-13 HU HUE15761201A patent/HUE046567T2/hu unknown
- 2015-03-13 CN CN201910710699.3A patent/CN110437153A/zh active Pending
- 2015-03-13 KR KR1020167028057A patent/KR102363174B1/ko active IP Right Grant
- 2015-03-13 SG SG10202001506UA patent/SG10202001506UA/en unknown
- 2015-03-13 WO PCT/US2015/020444 patent/WO2015138895A1/en active Application Filing
- 2015-03-13 RS RSP20191187 patent/RS59430B1/sr unknown
- 2015-03-13 MX MX2016011800A patent/MX363600B/es unknown
- 2015-03-13 ES ES15761201T patent/ES2748029T3/es active Active
- 2015-03-13 EP EP15761201.1A patent/EP3116316B1/en active Active
- 2015-03-13 CA CA2942533A patent/CA2942533C/en active Active
- 2015-03-13 AP AP2016009477A patent/AP2016009477A0/en unknown
- 2015-03-13 EP EP19184535.3A patent/EP3607950A3/en not_active Withdrawn
- 2015-03-13 PL PL15761201T patent/PL3116316T3/pl unknown
- 2015-03-13 JP JP2016557019A patent/JP6602311B2/ja active Active
- 2015-03-13 US US15/125,911 patent/US10183936B2/en active Active
- 2015-03-13 PT PT15761201T patent/PT3116316T/pt unknown
- 2015-03-13 DK DK15761201.1T patent/DK3116316T3/da active
- 2015-03-13 SG SG11201607268UA patent/SG11201607268UA/en unknown
- 2015-03-13 AU AU2015229174A patent/AU2015229174B2/en active Active
- 2015-03-13 CN CN201580024580.0A patent/CN106413402B/zh active Active
- 2015-03-13 EP EP21191660.6A patent/EP3974426A1/en not_active Withdrawn
-
2016
- 2016-08-31 IL IL247575A patent/IL247575B/en active IP Right Grant
- 2016-09-07 ZA ZA2016/06209A patent/ZA201606209B/en unknown
- 2016-09-07 DO DO2016000233A patent/DOP2016000233A/es unknown
- 2016-09-08 CL CL2016002269A patent/CL2016002269A1/es unknown
- 2016-09-08 PH PH12016501762A patent/PH12016501762A1/en unknown
- 2016-09-12 MX MX2019003525A patent/MX2019003525A/es unknown
-
2018
- 2018-04-27 US US15/965,655 patent/US10947224B2/en active Active
-
2019
- 2019-04-26 JP JP2019085742A patent/JP2019151650A/ja not_active Withdrawn
- 2019-05-29 AU AU2019203754A patent/AU2019203754A1/en not_active Abandoned
- 2019-08-09 HR HRP20191444 patent/HRP20191444T1/hr unknown
-
2020
- 2020-03-08 IL IL273132A patent/IL273132B/en active IP Right Grant
-
2021
- 2021-01-21 US US17/154,721 patent/US20230019129A1/en not_active Abandoned
- 2021-04-18 IL IL282391A patent/IL282391A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282391A (en) | Allosteric modulators of hepatitis B core protein | |
HK1259141A1 (zh) | 乙肝核心蛋白調節劑 | |
PL3303291T3 (pl) | Modulatory ROR-gamma | |
PL3303290T3 (pl) | Modulatory ROR-gamma | |
PL3303293T3 (pl) | Modulatory ROR-gamma | |
GB2554821B (en) | Modulating processor core operations | |
GB201414371D0 (en) | Protein modification | |
GB201412797D0 (en) | Proteins | |
GB201412648D0 (en) | Proteins | |
GB201412646D0 (en) | Proteins | |
GB201412649D0 (en) | Proteins | |
GB201406894D0 (en) | Proteins | |
GB201405952D0 (en) | Proteins | |
GB201405955D0 (en) | Proteins | |
GB201403915D0 (en) | Proteins | |
GB201403913D0 (en) | Proteins | |
GB201403914D0 (en) | Proteins | |
GB201403912D0 (en) | Proteins | |
GB201410682D0 (en) | Web-winding core |